全文获取类型
收费全文 | 4237篇 |
免费 | 306篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 77篇 |
妇产科学 | 142篇 |
基础医学 | 661篇 |
口腔科学 | 36篇 |
临床医学 | 405篇 |
内科学 | 816篇 |
皮肤病学 | 81篇 |
神经病学 | 526篇 |
特种医学 | 297篇 |
外科学 | 403篇 |
综合类 | 35篇 |
一般理论 | 5篇 |
预防医学 | 363篇 |
眼科学 | 57篇 |
药学 | 254篇 |
中国医学 | 5篇 |
肿瘤学 | 382篇 |
出版年
2023年 | 28篇 |
2022年 | 72篇 |
2021年 | 134篇 |
2020年 | 95篇 |
2019年 | 91篇 |
2018年 | 111篇 |
2017年 | 105篇 |
2016年 | 149篇 |
2015年 | 158篇 |
2014年 | 199篇 |
2013年 | 235篇 |
2012年 | 360篇 |
2011年 | 391篇 |
2010年 | 184篇 |
2009年 | 179篇 |
2008年 | 289篇 |
2007年 | 256篇 |
2006年 | 261篇 |
2005年 | 260篇 |
2004年 | 204篇 |
2003年 | 207篇 |
2002年 | 163篇 |
2001年 | 43篇 |
2000年 | 38篇 |
1999年 | 51篇 |
1998年 | 32篇 |
1997年 | 30篇 |
1996年 | 23篇 |
1995年 | 10篇 |
1994年 | 6篇 |
1993年 | 8篇 |
1992年 | 20篇 |
1991年 | 11篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 23篇 |
1987年 | 4篇 |
1986年 | 9篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1981年 | 4篇 |
1980年 | 8篇 |
1979年 | 6篇 |
1976年 | 5篇 |
1975年 | 5篇 |
1974年 | 3篇 |
1973年 | 4篇 |
1970年 | 8篇 |
1965年 | 3篇 |
排序方式: 共有4562条查询结果,搜索用时 78 毫秒
931.
Svjetlana Mohrmann Anna Maier-Bode Frederic Dietzel Petra Reinecke Natalia Krawczyk Thomas Kaleta Ulrike Kreimer Gerald Antoch Tanja N. Fehm Katrin Sabine Roth 《Breast care (Basel, Switzerland)》2022,17(2):159
BackgroundThe question of how to deal with B3 lesions is of emerging interest.MethodsIn the breast diagnostics of 192 patients between 2009 and 2016, a minimally invasive biopsy revealed a B3 lesion with subsequent resection. This study investigates the malignancy rate of different B3 subgroups and the risk factors that play a role in obtaining a malignant finding.ResultsThe distribution of B3 lesions after minimally invasive biopsy was as follows: atypical ductal hyperplasia (ADH), 7.3%; flat epithelial atypia (FEA), 7.8%; lobular neoplasia (LN), 7.8%; papilloma (Pa), 49.5%; phylloidal tumour (PT), 8.9%; radial sclerosing scar (RS), 3.1%; mixed findings, 10.4%; and other B3 lesions, 5.2%. Most B3 lesions were detected by stereotactic vacuum-assisted biopsy (44.3%), 36.5% by ultrasound-assisted biopsy, and 19.3% by magnetic resonance imaging-assisted biopsy. Most B3 lesions (55.2%) were verified by surgical resection, whereas 30.7% were downgraded to a benign lesion. About 14.1% of the cases were upgraded to malignant lesions, 9.4% to ductal carcinoma in situ and 4.7% to invasive carcinoma. In relation to individual B3 lesions, the following malignancy rates were found: 28.6% (ADH), 13.3% (FEA), 33.3% (LN), 12.6% (Pa), 5.9% (PT), and 0% (RS). The most important risk factor was increasing age. Postmenopausal status was considered an increased risk for an upgrade (p = 0.015). A known malignancy in the ipsilateral breast was a significant risk factor for a malignant upgrade (p = 0.003).ConclusionIncreasing knowledge about B3 lesions allows us to develop a “lesion-specific” therapy approach in the heterogeneous group of B3 lesions, with follow-up imaging for some lesions with less malignant potential and concordance with imaging or further surgical resection in cases of disconcordance with imaging or higher malignant potential. 相似文献
932.
Amelie de Gregorio Wolfgang Janni Thomas W. P. Friedl Ulrike Nitz Brigitte Rack Andreas Schneeweiss Ronald Kates Tanja Fehm Hans Kreipe Matthias Christgen Sherko Kümmel Elisabeth Trapp Rachel Wuerstlein Andreas Hartkopf Michael Clemens Toralf Reimer Lothar Hberle Peter A. Fasching Oleg Gluz Nadia Harbeck 《British journal of cancer》2022,126(12):1715
Background Anthracycline/cyclophosphamide-taxane-containing chemotherapy (AC-T) is the standard of care in the adjuvant treatment of HER2-negative early breast cancer (EBC), but recent studies suggest omission of anthracyclines for reduced toxicity without compromising efficacy.Methods Based on individual patient data (n = 5924) pooled from the randomised Phase III trials PlanB and SUCCESS C, we compared disease-free survival (DFS) and overall survival (OS) between intermediate to high-risk HER2-negative EBC-patients treated with either six cycles of docetaxel/cyclophosphamide (TC6) or an AC-T regime using univariable and adjusted multivariable Cox regression models.Results AC-T conferred no significant DFS or OS advantage in univariable (DFS: hazard ratio (HR) for TC vs. AT 1.05, 95% confidence interval (CI): 0.89–1.24, P = 0.57; OS: HR 1.00, 95% CI: 0.80–1.26, P = 1.00) and adjusted multivariable analysis (DFS: HR 1.01, 95% CI: 0.86–1.19, P = 0.91; OS: HR 0.97, 95% CI: 0.77–1.22, P = 0.79). Patients receiving TC6 had significantly fewer grade 3–4 adverse events. Exploratory subgroup analysis showed that AC-T was associated with significantly better DFS and OS in pN2/3 patients, specifically in those with lobular histology.Conclusion For most patients with HER2-negative EBC, AC-T is not associated with a survival benefit compared to TC6. However, patients with lobular pN2/pN3 tumours seem to benefit from anthracycline-containing chemotherapy.Subject terms: Randomized controlled trials, Breast cancer 相似文献
933.
Exploring Educational Disparities in Risk of Preterm Delivery: A Comparative Study of 12 European Birth Cohorts 下载免费PDF全文
Gry Poulsen Katrine Strandberg‐Larsen Laust Mortensen Henrique Barros Sylvaine Cordier Sofia Correia Asta Danileviciute Manon van Eijsden Ana Fernández‐Somoano Ulrike Gehring Regina Grazuleviciene Esther Hafkamp‐de Groen Tine Brink Henriksen Morten Søndergaard Jensen Isabel Larrañaga Per Magnus Kate Pickett Hein Raat Lorenzo Richiardi Florence Rouget Franca Rusconi Camilla Stoltenberg Eleonora P. Uphoff Tanja G. M. Vrijkotte Alet H. Wijga Martine Vrijheid Merete Osler Anne‐Marie Nybo Andersen 《Paediatric and perinatal epidemiology》2015,29(3):172-183
934.
935.
Tanja Stachon Jiong Wang Achim Langenbucher Timo Eppig Markus Bischoff Berthold Seitz Nóra Szentmáry 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2013,251(11):2585-2590
Purpose
With increasing resistance of microorganisms to antibiotics, photodynamic inactivation (PDI) may also be a potential therapeutic option in infectious keratitis. As part of the inflammatory response in infectious keratitis, keratocytes produce various interleukins. The purpose of this study was to evaluate the potential anti-inflammatory effect of PDI, analyzing interleukin-1 alpha (IL-1α), interleukine-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-8 (IL-8) secretion of human keratocytes following PDI, in vitro.Methods
Primary human keratocytes were isolated by digestion in collagenase A (1.0 mg/ml) from human corneal buttons, and cultured in DMEM/Ham’s F12 medium supplemented with 10 % FCS. Keratocyte cell cultures underwent illumination using red (670 nm) light for 13 min following exposure to 100 nM concentration of the photosensitizer chlorin e6 (Ce6) in the culture medium. Five and 24 hours after PDI, secretion of IL-1α, IL-1β, IL-6, and IL-8 was measured by enzyme-linked immunoabsorbent assay (ELISA).Results
The secretion of IL-1α was under the measurement limit in treated and untreated cell cultures 5 and 24 h after PDI. Compared to untreated controls, IL-6 and IL-8 secretion of keratocytes decreased (p?<?0.05 and 0.0001) significantly 5 hours after PDI, whereas IL-1β secretion remained unchanged. Twenty-four hours after PDI, secretion of IL-1β, IL-6, and IL-8 did not differ significantly from untreated controls.Conclusions
In the short term, PDI does not have an impact on IL-1α and IL-1β secretion of keratocytes, in vitro. Photodynamic inactivation inhibits IL-6 and IL-8 secretion of keratocytes transiently (5 h), which normalizes 24 h following treatment. Through the short-term impact of chlorine e6-PDI on IL-6 and IL-8 secretion, PDI may inhibit the inflammatory cascade in at least keratocyte cultures. 相似文献936.
François-Clément Bidard Dieter J Peeters Tanja Fehm Franco Nolé Rafael Gisbert-Criado Dimitrios Mavroudis Salvatore Grisanti Daniele Generali Jose A Garcia-Saenz Justin Stebbing Carlos Caldas Paola Gazzaniga Luis Manso Rita Zamarchi Angela Fernandez de Lascoiti Leticia De Mattos-Arruda Michail Ignatiadis Ronald Lebofsky Stefan Michiels 《The lancet oncology》2014,15(4):406-414
937.
938.
Volkmar Müller Sabine Riethdorf Brigitte Rack Wolfgang Janni Peter A Fasching Erich Solomayer Bahriye Aktas Sabine Kasimir-Bauer Klaus Pantel Tanja Fehm 《Breast cancer research : BCR》2012,14(4):1-8
Introduction
There is a multitude of assays for the detection of circulating tumor cells (CTCs) but a very limited number of studies comparing the clinical relevance of results obtained with different test methods. The DETECT trial for metastatic breast cancer patients was designed to directly compare the prognostic impact of two commercially available CTC assays that are prominent representatives of immunocytochemical and RT-PCR based technologies.Methods
In total, 254 metastatic breast cancer patients were enrolled in this prospective multicenter trial. CTCs were assessed using both the AdnaTest Breast Cancer and the CellSearch system according to the manufacturers' instructions.Results
With the CellSearch system, 116 of 221 (50%) evaluable patients were CTC-positive based on a cut-off level at 5 or more CTCs. The median overall survival (OS) was 18.1 months in CTC-positive patients. (95%-CI: 15.1-22.1 months) compared to 27 months in CTC-negative patients (23.5-30.7 months; p<0.001). This prognostic impact for OS was also significant in the subgroups of patients with triple negative, HER2-positive and hormone receptor-positive/HER2-negative primary tumors. The progression free survival (PFS) was not correlated with CTC status in our cohort receiving different types and lines of systemic treatment (p = 0.197). In multivariate analysis, the presence of CTCs was an independent predictor for OS (HR: 2.7, 95%-CI: 1.6-4.2). When the AdnaTest Breast was performed, 88 of 221 (40%) patients were CTC-positive. CTC-positivity assessed by the AdnaTest Breast had no association with PFS or OS.Conclusions
The prognostic relevance of CTC detection in metastatic breast cancer patients depends on the test method. The present results indicate that the CellSearch system is superior to the AdnaTest Breast Cancer in predicting clinical outcome in advanced breast cancer.Trial registration
Current Controlled Trials Registry number ISRCTN59722891. 相似文献939.
Marko Bitenc Tanja Cufer Izidor Kern Martina Miklavcic Sabrina Petrovic Vida Groznik Aleksander Sadikov 《Radiology and oncology》2022,56(3):346
BackgroundTreatment of early-stage non-small cell lung cancer (NSCLC) is rapidly evolving. When introducing novelties, real-life data on effectiveness of currently used treatment strategies are needed. The present study evaluated outcomes of stage I–IIIA NSCLC patients treated with upfront radical surgery in everyday clinical practice, between 2010–2017.Patients and methodsData of 539 consecutive patients were retrieved from a prospective hospital-based registry. All diagnostic, treatment and follow-up procedures were performed at the same thoracic oncology centre according to the valid guidelines. The primary outcome was overall survival (OS) analysed by clinical(c) and pathological(p) TNM (tumour, node, metastases) stage. The impact of clinicopathological characteristics on OS was evaluated using univariable (UVA) and multivariable regression analysis (MVA).ResultsWith a median follow-up of 53.9 months, median OS and 5-year OS rate in the overall population were 90.4 months and 64.4%. Five-year OS rates by pTNM stage I, II and IIIA were 70.2%, 60.21%, and 49.9%, respectively. Both cTNM and pTNM stages were associated with OS; but only pTNM retained its independent prognostic value (p = 0.003) in MVA. Agreement between cTNM and pTNM was 69.0%. Next to pTNM, age (p = 0.001) and gender (p = 0.004) retained their independent prognostic value for OS.ConclusionsThe study showed favourable outcomes of resectable stage I–IIIA NSCLC treated with upfront surgery in real-life. Relatively low agreement between cTNM and pTNM stages and independent prognostic value of only pTNM, observed in real-life data, suggest that surgery remains the most accurate provider of the anatomical stage of disease and important upfront therapy.Key words: resectable NSCLC, upfront surgery, real-life data, overall survival, prognostic factors 相似文献
940.
Sonja Adebahr Marlene Hechtner Nele Schräder Tanja Schimek-Jasch Klaus Kaier Viola Duncker-Rohr Eleni Gkika Felix Momm Jan Gaertner Gerhild Becker Anca-Ligia Grosu Ursula Nestle 《Journal of thoracic oncology》2019,14(3):408-419